TriSalus Life Sciences, Inc. (TLSI)
| Market Cap | 333.12M +46.8% |
| Revenue (ttm) | 45.08M +25.2% |
| Net Income | -57.25M |
| EPS | -1.15 |
| Shares Out | 61.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,000 |
| Open | 5.47 |
| Previous Close | 5.40 |
| Day's Range | 5.40 - 5.52 |
| 52-Week Range | 2.20 - 7.95 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+84.84%) |
| Earnings Date | Aug 6, 2026 |
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device... [Read more]
Financial Performance
In 2025, TriSalus Life Sciences's revenue was $45.15 million, an increase of 53.41% compared to the previous year's $29.43 million. Losses were -$69.69 million, 109.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 84.84% from the latest price.
News
TriSalus Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
A smart valve catheter technology is driving improved drug delivery and outcomes in solid tumors, with imminent FDA clearance for TriNav ADVANCE expected to expand the addressable market by 20%. Strong clinical evidence, new reimbursement codes, and a scaled sales force position the company for significant near-term growth.
TriSalus Life Sciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew to $11.4M, driven by TriNav demand and commercial expansion. CMS approved a G-code for OBL reimbursement, broadening market access. Full-year revenue guidance of $54–$57M was reiterated, with sequential growth and cost discipline expected.
TriSalus Life Sciences Earnings release: Q2 2026
TriSalus Life Sciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
TriSalus Life Sciences Quarterly report: Q2 2026
TriSalus Life Sciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
TriSalus Life Sciences Reports Second Quarter 2026 Results
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an inves...
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immun...
TriSalus Life Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw a deliberate commercial expansion, leading to a temporary revenue dip but positioning for multi-year growth. Landmark PEDD study validated significant clinical and economic benefits, while 2026 revenue guidance was revised to $54–57 million due to FDA delays and transition costs.
TriSalus Life Sciences Earnings release: Q1 2026
TriSalus Life Sciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
TriSalus Life Sciences Quarterly report: Q1 2026
TriSalus Life Sciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Slides: Investor presentation
TriSalus Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Proxy statement: Proxy filing
TriSalus Life Sciences filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
TriSalus Life Sciences Proxy statement: Proxy filing
TriSalus Life Sciences filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences Earnings Call Transcript: Q4 2025
Revenue grew 60% in Q4 and 53% for the year, driven by commercial execution and product expansion. A $46M public offering strengthened the balance sheet, enabling investments in sales force and clinical studies. 2026 revenue guidance is $60–$62M, with growth weighted to H2.
TriSalus Life Sciences Annual report: Q4 2025
TriSalus Life Sciences has published its Q4 2025 annual report on March 5, 2026.
TriSalus Life Sciences Earnings release: Q4 2025
TriSalus Life Sciences released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...